Global Allergic Conjunctivitis Treatment Market Report and Forecast 2024-2032

Global Allergic Conjunctivitis Treatment Market Outlook

The allergic conjunctivitis treatment market size was estimated to be worth USD 8 billion in 2023, driven by the increasing incidences of ocular injuries. The market is expected to rise at a CAGR of 3.95% during the forecast period of 2024-2032. By 2032, the market value is anticipated to be worth USD 11.30 billion.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Allergic Conjunctivitis: Disease Insights

Allergic conjunctivitis is an ocular allergy caused by foreign agents like household dust, animal dander, pollen, chemical scents, or mould spores. The inflammation in the eye is caused due to an allergic reaction to allergens. Depending on the duration, allergic conjunctivitis can be of two types: Acute and Chronic.

Acute allergic conjunctivitis is the most common type and stays for a short term, while chronic one stays for a year or longer, and symptoms come and go as per the environmental conditions.

The human body produces a potent chemical, histamine in response to any foreign agents. As the allergens enter the eye, the body releases histamine as a defence mechanism. This leads to irritation, itching, and inflammation in the eye.

Diagnosis and Treatment Aiding the Allergic Conjunctivitis Treatment Market Growth

The diagnosis of the condition is done through eye monitoring and ophthalmological tests. An allergy skin test is also used to confirm the incidence of allergic conjunctivitis. The antibodies produced by the body are detected through blood tests. This is also an effective diagnostic procedure for allergic conjunctivitis disease.

There are no specific treatment guidelines for the management of allergic conjunctivitis. Home care remedies include washing the eyes and applying a cool compress to the eyes. In case of a severe problem, medications are used for the treatment. The anti-histaminic drugs, anti-inflammatory eye drugs, or eye drops can be used to alleviate allergic symptoms.

According to this study, the market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Diagnosis

• Allergy Skin Test

• Blood Test

• Others

Market Breakup by Drug Class

• Antihistamines and Mast Cell Stabilisers

• Corticosteroids

• NSAIDS

• Others

Market Breakup by Disease Type

• Seasonal Allergic Conjunctivitis

• Contact Conjunctivitis

• Giant Papillary Conjunctivitis

• Perennial Conjunctivitis

• Vernal Keratoconjunctivitis

• Atopic Keratoconjunctivitis

Market Breakup by Treatment Channel

• Public

• Private

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Allergic Conjunctivitis Treatment Market Scenario

The increase in the incidence of ocular allergies is the primary reason for market development. Due to rapid urbanisation and rising allergens, the susceptibility to allergic conjunctivitis increases. This is driving the growth of the market.

Increasing awareness has led to more adoption of medications and drugs for the management of ophthalmological problems. This has facilitated the demand of the treatment market. Easy availability and accessibility have also been attributed to the increased allergic conjunctivitis treatment market growth.

Increased investments in research and developmental activities, a major influx of generic drugs and a rising population, are some of the additional factors contributing to the growth of the market.

Antihistamines Account for the Largest Share 

Among the drug classes, antihistamines are anticipated to have the largest share in the allergic conjunctivitis treatment market. Antihistamines and mast cell stabilizers are the cornerstone therapy for the management of allergic problems. Novel product launches in this drug class are also expected to boost the growth of the market during the forecast period.

Regional Outlook: North America, Europe, and the Asia Pacific Possess Significant Shares

North America is expected to have the greatest share in the market owing to the increased prevalence, greater awareness, and presence of significant key players in that region.

Following North America, Europe is projected to dominate among all the regional markets. The factors contributing to this share are more usage of sophisticated medications and the rising patient population.

The Asia Pacific region is anticipated to be the fastest-growing region in the allergic conjunctivitis treatment market. This is attributed to the raising awareness and significant improvements in the healthcare sector.

Therapeutic Landscape

Allergic Conjunctivitis is caused due to the overreaction of the immune system of the body towards an allergic response. There are different therapeutic options for the management of allergic conjunctivitis depending on the type and severity of the allergy. A major part of therapeutic interventions is also used as a precautionary measure against environmental allergies.

Drug Treatment: Antihistamines, Mast Cell Stabilisers, and Corticosteroids

Antihistamines, mast cell stabilisers, and corticosteroids are used to treat allergic symptoms. Drug treatment is the first line of treatment for allergic conjunctivitis. Antihistamines block the secretion of histamines, which are released due to the reaction of an immune system. Oral histamines and eye drops are the two forms of administration. Examples of antihistamines are cetirizine, loratadine, ketotifen and azelastine.

Mast cell stabilisers stabilise the mast cells and take a bit longer time to show their effect. These medications are administered in the form of eye drops. The most used mast cell stabilisers are nedocromil and lodoxamide. 

Corticosteroids are only used in case of severe symptoms. These medications reduce inflammation and help in lowering the body’s immune response. These drugs should be used in short term due to their side effects.

There are other additional treatments used for alleviating symptoms. Artificial tears are the oral eye drops used to dilute the allergen and help in its elimination. Cold compresses are applied to provide a soothing effect to the eye and provides a relaxing effect. 

Clinical Trials

The currently available medications and therapeutic interventions are optimal for the management of allergic conjunctivitis. However, preclinical, and clinical studies are under process to discover novel medications that are more effective and have lesser side effects.

Undergoing Clinical Trials are Anticipated to Boost the Allergic Conjunctivitis Treatment Market Growth

Topical steroids are commonly used for managing allergic symptoms. Clinical trials are being done for ester-based steroids, which are anticipated to have fewer adverse effects and better therapeutic potential. Mapracorat is presently under clinical studies. It reduces the uptake of eosinophils and helps in reducing inflammation.

Cyclosporine A is currently under clinical trials for assessing its efficacy and other side effects. The discovery of cyclosporine will reduce the reliance on topical steroids. Clinical studies are under process for determining the optimal cyclosporin concentration for distinct types of allergic conjunctivitis. Researchers are also conducting pre-clinical studies to check drug safety in the paediatric population.

Japan is conducting clinical trials for the ophthalmic application of calcineurin inhibitors. Tacrolimus eye drops are under research and have shown promising results in the early phases of clinical testing. This medication is under advanced testing for further evaluation.

The discovery of these novel therapeutic interventions will assist in the proper diagnosis and treatment of allergic conjunctivitis. The novel product launches will facilitate the expansion of the market.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the allergic conjunctivitis treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Sun Pharmaceutical Industries Limited

• Novartis AG

• Bausch & Lomb

• AbbVie Inc.

• Ocular Therapeutix, Inc.

• Alexion Pharmaceuticals Inc.

• Santen Pharmaceutical Co., Ltd.

• Dr. Reddy’s Laboratories Ltd.

• Alembic Pharmaceuticals Ltd.

• Grevis Pharmaceuticals Pvt. Ltd.

Key Highlights of the Report